Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
ID: HT9402-25-Q-9102Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYAURORA, CO, 80011, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f4bb38e3b231424dadb1175bc4d5daad/view
Timeline
    Description

    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.

    Point(s) of Contact
    Tracy Banks
    tracy.e.banks2.civ@mail.mil
    Julia Trang
    julia.n.trang.civ@health.mil
    Files
    Title
    Posted
    DoD Formulary Placement of FDA Newly Approved Drugs.pdf
    The document outlines the process for the formulary placement of newly approved innovator drugs within the Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/TRICARE Pharmacy Benefits Program, following the Final Rule published on July 27, 2015. The Pharmacy and Therapeutics (P&T) Committee is responsible for evaluating these drugs, classified under various chemical types, and has up to 120 days to recommend their tier placement on the uniform formulary. Newly approved drugs after August 26, 2015, will initially hold a pending status and will be reviewed quarterly for placement, considering clinical and cost-effectiveness. Prices must be available 30 days prior to meetings to avoid deferrals. Manufacturers can submit price concessions during specified solicitation windows, with drugs being categorized from Tier 1 to Tier 4/Not Covered based on the Committee's evaluations. Tier 3 designation generally limits these drugs' availability, except in cases where medical necessity is proven. The document emphasizes the structured approach to drug assessment, highlighting the Department of Defense’s efforts to ensure effective drug management in military healthcare.
    Price Appendix FAQ NAD.pdf
    The document outlines the procedures and requirements for submitting quotes for various drug-related categories within a government context. It provides detailed instructions for three main pricing frameworks: BPA (basic pricing agreements), ADP (non-FAMP and WAC discounts). Each section emphasizes the importance of filling in specified fields, indicated with yellow cells, and highlights how certain inputs auto-populate related fields, streamlining the data submission process. Key points include the necessity of understanding the P&T committee’s formulary decision-making process, the importance of correctly entering pricing information for National Drug Codes (NDCs), and the implications of submitting zero discounts, which will be flagged for the committee’s attention. Furthermore, it outlines guidelines for submitting more than the initial 10 NDCs by contacting designated points of contact. Overall, the document serves as a comprehensive guide for vendors seeking to participate in federal drug procurement, ensuring adherence to specific data entry protocols and emphasizing the significance of accurate pricing information in the context of governmental requests for proposals (RFPs). It aims to facilitate efficient bid submissions while maintaining compliance with federal standards and formularies.
    Price List - Itovebi - Oncological Agents - Breast Cancer.xlsx
    The document outlines the upcoming Pharmaceutical and Therapeutics (P&T) Committee Meeting scheduled for February 5-6, 2025, focusing on oncological agents specifically for breast cancer. It sets a deadline for quotes from manufacturers for newly approved drugs by December 19, 2024. The document details the approval process governed by the Department of Defense (DOD) Uniform Formulary, where drugs may be categorized as uniform or non-formulary based on specific pricing and usage criteria. Key elements include price per National Drug Code (NDC) and dosage forms, along with conditions for potential discounts through programs like TRICARE Retail Refund. The P&T Committee evaluates drugs for potential high-value status and may recommend exclusions from the TRICARE pharmacy benefit program. Essential procedural notes and conditions regarding prior authorization, step therapy, and manufacturers' responsibilities in submitting documentation are emphasized. The document serves as a guide for suppliers intending to engage with the Department of Defense’s formulary system, ensuring transparency and compliance with federal regulations for the procurement of oncological drugs.
    Price List - Miplyffa - Neurological Agents Miscellaneous - NA.xlsx
    The document pertains to the Department of Defense (DoD) Uniform Formulary for Neurological Agents Miscellaneous, presented for the P&T Committee meeting scheduled for February 5-6, 2025. It outlines the process for suppliers to submit quotes for newly approved drugs, with a submission deadline set for December 19, 2024. The document describes the requirement for submitted quotes to include specific details such as National Drug Code (NDC) number, drug name, strength, dosage form, and package size, while cautioning that lack of submission may highlight a company's intent not to participate. Additionally, it emphasizes that these agents may require prior authorization and may be eligible for special reimbursement methods aimed at encouraging the use of high-value products. The P&T Committee has the authority to recommend preferential treatment for certain non-generic pharmaceutical agents and can also identify drugs for exclusion from the TRICARE pharmacy benefit program. The overarching purpose of the document is to guide manufacturers in navigating the formulary submission process while ensuring compliance with the DoD's pharmaceutical procurement criteria, ultimately supporting the military healthcare system's drug formulary management.
    Price List - Opipza - Antipsychotic Agents - Atypical.xlsx
    The document outlines the upcoming Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee meeting scheduled for February 5-6, 2025, focusing on antipsychotic agents, specifically atypical agents. It details a timeline for submitting quotes by December 19, 2024, for newly approved drugs, along with certain stipulations for the manufacturers. The proposal includes various scenarios emphasizing the need for price quotations for Uniform and Non-Formulary drugs, indicating that no quotes have been received thus far. The additional discount program appendices detail TRICARE retail refunds and requirements for submission, stressing the importance of confirming intent to quote. The document specifies that a prior authorization (PA) may be applicable for agents reviewed. The main goal is to facilitate contracts for pharmaceuticals while evaluating their reimbursement methods, promoting high-value products, and potentially altering their formulary status based on cost-sharing strategies. Overall, the document highlights the structured approach to enhancing DoD pharmacy services amidst regulatory standards aimed at ensuring effective healthcare support for its members.
    RFQ HT9402-25-Q-9102 NAD.pdf
    The Department of Defense (DoD) has issued a Request for Quotation (RFQ) related to the procurement of pharmaceutical agents for the Military Health System via the Defense Health Agency and the Pharmacy and Therapeutics Committee. This RFQ outlines the process by which pharmaceutical companies can submit price quotes for agents to be included in the Uniform Formulary (UF), which classifies drugs into tiers based on cost-effectiveness and clinical efficacy. Key components include instructions for quote submissions, government-provided data, and criteria for evaluating and awarding Blanket Purchase Agreements (BPA) and Additional Discount Programs (ADP). Companies must provide comprehensive pricing information, including National Drug Code (NDC) lists, and adhere to strict regulations regarding the inclusion of their pharmaceuticals in designated formularies. The document underscores the importance of compliance and transparency in pricing, with final approvals contingent upon evaluations by the DoD Pharmacy and Therapeutics Committee. The overarching goal is to ensure an effective and cost-efficient pharmacy benefits program for military health beneficiaries while facilitating competitive pricing from manufacturers.
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense (DoD) is seeking quotes for a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) related to the procurement of pharmaceutical agents as part of its Uniform Formulary (UF) initiative. This procurement aims to establish an effective and integrated pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of newly approved drugs, including neurological agents, antibiotics, oncological agents, and various other pharmaceutical categories. Interested manufacturers must submit their quotes by January 16, 2025, with a pre-quotation teleconference scheduled for January 8, 2025, to discuss the requirements and expectations. For further inquiries, manufacturers can contact Tracy Banks at tracy.e.banks2.civ@health.mil or Patricia Tyson at patricia.a.tyson3.ctr@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotations for pharmaceutical agents to be included in the Uniform Formulary (UF) as part of its pharmacy benefits program for the Military Health System (MHS). This procurement aims to establish Blanket Purchase Agreements (BPAs) and Additional Discount Programs (ADPs) for cost-effective pharmaceutical options, ensuring that the selected agents meet clinical and cost-effectiveness criteria as evaluated by the Pharmacy and Therapeutics (P&T) Committee. The initiative is critical for providing safe and effective medications to military beneficiaries while managing costs within the healthcare system. Interested manufacturers must submit their quotes by December 30, 2024, and can direct inquiries to Tracy Banks or Keith Marasigan via their respective emails for further information.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Cyclobenzaprine Tablets (VA-25-00015093)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Cyclobenzaprine HCL Tablets under solicitation number 36E79725R0009. This unrestricted procurement aims to secure a reliable supply of these essential pharmaceuticals for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC), reflecting the government's commitment to providing necessary medications to veterans and associated healthcare systems. The contract will have an initial duration of one year, with the possibility of four additional one-year extensions, and interested vendors must provide specific drug labeling along with a unique National Drug Code (NDC). The RFP is expected to be released electronically around December 20, 2024, with a submission deadline set for January 3, 2025. For further inquiries, interested parties can contact Kenneth Lay at Kenneth.Lay@va.gov or by phone at 708-786-4879.
    Doxycycline Hyclate Solicitation
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Doxycycline Hyclate tablets under solicitation number SPE2D2-25-R-0004. This procurement aims to secure pharmaceutical products in various quantities and packaging configurations, with specific requirements outlined for compliance with federal regulations, including business ethics and subcontracting plans. Doxycycline Hyclate is a critical antibiotic used in various medical applications, making this procurement essential for maintaining adequate supplies for military and healthcare operations. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Courtney Hunter-Stangler or Jason C. Wray for further information regarding the solicitation.
    6505--765_Pharmaceuticals_VA CMOP Hines_36C77025Q0088 765-25-1-021-0194 -Hines CMOP 4 PHARMACEUTICALS -(VA-25-00028394)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified vendors to supply various pharmaceuticals for delivery to the Consolidated Mail Outpatient Pharmacy (CMOP) in Hines, Illinois, under solicitation number 36C77025Q0088. The procurement includes specific items such as PEG-400 solution, Sevelamer carbonate tablets, Fenofibrate capsules, and Febuxostat tablets, with a total quantity specified for each item. These pharmaceuticals are essential for ensuring the health and well-being of veterans, highlighting the importance of a reliable supply chain in the healthcare sector. Interested vendors must submit their quotes, including a signed SF 1449 cover page and compliance documentation, by December 27, 2024, at 9:00 AM CST, with the estimated award date set for December 31, 2024. For further inquiries, vendors can contact Jeffrey A. Blackard at jeffrey.blackard@va.gov or by phone at (913) 684-0142.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting offers for the supply of Norgestimate/Ethinyl Estradiol Tablets, a pharmaceutical product essential for oral contraceptive use. The procurement aims to establish a contract that outlines specific supply requirements, estimated quantities for multiple option years, and compliance with federal regulations, including ethical conduct and labor standards. This solicitation is critical for ensuring the availability of these contraceptive medications to support military personnel and their families. Interested contractors must submit their offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Kyle Lewicki at kyle.lewicki@dla.mil or Jason C. Wray at Jason.Wray@dla.mil for further information.
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Repaglinide
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.